Sesen Bio announced the appointments of Minori Rosales, M.D., Ph.D. as Chief Development Officer as of January 24, 2022 and Stephanie Vigue as Director of Finance as of January 17, 2022. Dr. Rosales will be responsible for medical and clinical strategic and operational leadership across the organization, including leading and executing an additional Phase 3 clinical trial for Vicineum™ for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. She brings over 15 years of clinical experience in pharmaceutical development, most recently as Vice President, Clinical Research at MacroGenics, where she oversaw clinical development, including execution of clinical studies and management of global clinical safety and compliance, and led interactions with regulatory agencies.

Prior to joining MacroGenics in 2018, Dr. Rosales held a Vice President role at the subsidiary of AstraZeneca formerly known as MedImmune. In this role, Dr. Rosales was responsible for leading a global cross-functional team for development of immuno-oncology products in Genitourinary cancers and biomarker development for tumor indications. She holds an M.D. from Yamaguchi University's School of Medicine and a Ph.D. in Tumor Immunology from Kansai Medical University, both in Japan.

Ms. Vigue will lead the Company's financial planning and analysis function, including developing the Company's annual budget, managing long-range strategic and financial planning and partnering with the clinical development team on financial aspects of executing an additional Phase 3 clinical trial. She has over a decade of experience in corporate accounting and finance, most recently serving as Corporate Accounting Manager/Interim Controller at The Fi Company, where she managed daily operations of the company's finance department.